Cargando…
Metabolic signature of obesity-associated insulin resistance and type 2 diabetes
BACKGROUND: Obesity is associated with an increased risk of insulin resistance and type 2 diabetes mellitus (T2DM). However, some obese individuals maintain their insulin sensitivity and exhibit a lower risk of associated comorbidities. The underlying metabolic pathways differentiating obese insulin...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805293/ https://www.ncbi.nlm.nih.gov/pubmed/31640727 http://dx.doi.org/10.1186/s12967-019-2096-8 |
_version_ | 1783461348231872512 |
---|---|
author | Al-Sulaiti, Haya Diboun, Ilhame Agha, Maha V. Mohamed, Fatima F. S. Atkin, Stephen Dömling, Alex S. Elrayess, Mohamed A. Mazloum, Nayef A. |
author_facet | Al-Sulaiti, Haya Diboun, Ilhame Agha, Maha V. Mohamed, Fatima F. S. Atkin, Stephen Dömling, Alex S. Elrayess, Mohamed A. Mazloum, Nayef A. |
author_sort | Al-Sulaiti, Haya |
collection | PubMed |
description | BACKGROUND: Obesity is associated with an increased risk of insulin resistance and type 2 diabetes mellitus (T2DM). However, some obese individuals maintain their insulin sensitivity and exhibit a lower risk of associated comorbidities. The underlying metabolic pathways differentiating obese insulin sensitive (OIS) and obese insulin resistant (OIR) individuals remain unclear. METHODS: In this study, 107 subjects underwent untargeted metabolomics of serum samples using the Metabolon platform. Thirty-two subjects were lean controls whilst 75 subjects were obese including 20 OIS, 41 OIR, and 14 T2DM individuals. RESULTS: Our results showed that phospholipid metabolites including choline, glycerophosphoethanolamine and glycerophosphorylcholine were significantly altered from OIS when compared with OIR and T2DM individuals. Furthermore, our data confirmed changes in metabolic markers of liver disease, vascular disease and T2DM, such as 3-hydroxymyristate, dimethylarginine and 1,5-anhydroglucitol, respectively. CONCLUSION: This pilot data has identified phospholipid metabolites as potential novel biomarkers of obesity-associated insulin sensitivity and confirmed the association of known metabolites with increased risk of obesity-associated insulin resistance, with possible diagnostic and therapeutic applications. Further studies are warranted to confirm these associations in prospective cohorts and to investigate their functionality. |
format | Online Article Text |
id | pubmed-6805293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68052932019-10-24 Metabolic signature of obesity-associated insulin resistance and type 2 diabetes Al-Sulaiti, Haya Diboun, Ilhame Agha, Maha V. Mohamed, Fatima F. S. Atkin, Stephen Dömling, Alex S. Elrayess, Mohamed A. Mazloum, Nayef A. J Transl Med Research BACKGROUND: Obesity is associated with an increased risk of insulin resistance and type 2 diabetes mellitus (T2DM). However, some obese individuals maintain their insulin sensitivity and exhibit a lower risk of associated comorbidities. The underlying metabolic pathways differentiating obese insulin sensitive (OIS) and obese insulin resistant (OIR) individuals remain unclear. METHODS: In this study, 107 subjects underwent untargeted metabolomics of serum samples using the Metabolon platform. Thirty-two subjects were lean controls whilst 75 subjects were obese including 20 OIS, 41 OIR, and 14 T2DM individuals. RESULTS: Our results showed that phospholipid metabolites including choline, glycerophosphoethanolamine and glycerophosphorylcholine were significantly altered from OIS when compared with OIR and T2DM individuals. Furthermore, our data confirmed changes in metabolic markers of liver disease, vascular disease and T2DM, such as 3-hydroxymyristate, dimethylarginine and 1,5-anhydroglucitol, respectively. CONCLUSION: This pilot data has identified phospholipid metabolites as potential novel biomarkers of obesity-associated insulin sensitivity and confirmed the association of known metabolites with increased risk of obesity-associated insulin resistance, with possible diagnostic and therapeutic applications. Further studies are warranted to confirm these associations in prospective cohorts and to investigate their functionality. BioMed Central 2019-10-22 /pmc/articles/PMC6805293/ /pubmed/31640727 http://dx.doi.org/10.1186/s12967-019-2096-8 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Al-Sulaiti, Haya Diboun, Ilhame Agha, Maha V. Mohamed, Fatima F. S. Atkin, Stephen Dömling, Alex S. Elrayess, Mohamed A. Mazloum, Nayef A. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
title | Metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
title_full | Metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
title_fullStr | Metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
title_full_unstemmed | Metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
title_short | Metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
title_sort | metabolic signature of obesity-associated insulin resistance and type 2 diabetes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805293/ https://www.ncbi.nlm.nih.gov/pubmed/31640727 http://dx.doi.org/10.1186/s12967-019-2096-8 |
work_keys_str_mv | AT alsulaitihaya metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT dibounilhame metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT aghamahav metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT mohamedfatimafs metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT atkinstephen metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT domlingalexs metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT elrayessmohameda metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes AT mazloumnayefa metabolicsignatureofobesityassociatedinsulinresistanceandtype2diabetes |